Published September 30, 2019 | Version v1
Dataset Open

Purification of HTT Q23 and Q54 from EXPI293F for mass spectrometry analysis 2019/09/30

  • 1. Structural Genomics Consortium, University of Toronto


Project: Biophysical investigation of purified HTT protein samples

Experiment: Purification of Q23 and Q54 HTT from EXPI293F

Date completed:­ 2019/09/30

Rationale: Purify HTT Q23 and Q54 for mass spectrometry analysis


Dr. Harding is the recipient of the Huntington's Disease Society of America Berman Topper Career Development Fellowship which funds and supports this research, in addition to generous funding from the CHDI Foundation and the Huntington Society of Canada. The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada through Ontario Genomics Institute [OGI-055], Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck KGaA, Darmstadt, Germany, MSD, Novartis Pharma AG, Ontario Ministry of Research, Innovation and Science (MRIS), Pfizer, São Paulo Research Foundation-FAPESP, Takeda, and Wellcome.


Purify HTT Q23 and Q54 for mass spectrometry analysis 20190930.pdf